FFA
BCRX icon

Farther Finance Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

Farther Finance Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$51.1K Sell
6,138
-413
-6% -$3.89K ﹤0.01% 3403
2026
Q2 		$64.8K Buy
6,551
+861
+15% +$7.79K ﹤0.01% 3042
2026
Q1 		$53.4K Sell
5,690
-5,802
-50% -$45.1K ﹤0.01% 2956
2025
Q4 		$89.6K Buy
11,492
+902
+9% +$6.52K ﹤0.01% 2413
2025
Q3 		$80.4K Buy
10,590
+8,109
+327% +$67.5K ﹤0.01% 2166
2025
Q2 		$22.2K Buy
2,481
+19
+0.8% +$177 ﹤0.01% 2613
2025
Q1 		$17.9K Buy
+2,462
New +$19.9K ﹤0.01% 2443
2024
Q2 		– Sell
-60
Closed -$303 – 3830
2024
Q1 		$303 Buy
+60
New +$337 ﹤0.01% 3162

Other funds holding BCRX

WCM
Wedge Capital Management Charlotte, North Carolina $5.72B AUM 38.26% 1-Year Est. Return
DA
Doliver Advisors Houston, Texas $458M AUM 38.24% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
MBI
May Barnhard Investments Bethesda, Maryland $243M AUM 13.89% 1-Year Est. Return
CIM
Contravisory Investment Management Norwell, Massachusetts $552M AUM 32.44% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
RF
RHS Financial San Francisco, California $296M AUM 17.24% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

Farther Finance Advisors's BCRX Position: Q3 2026 in Review

Farther Finance Advisors reduced its BioCryst Pharmaceuticals (BCRX) stake by 6.3% in Q3 2026, selling an estimated $3.89K and leaving 6,138 shares worth $51.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3403.

Farther Finance Advisors first reported a position in BCRX in Q1 2024 and has held it in 8 quarters since. The position peaked at $89.6K in Q4 2025. 11 funds tracked by Wall St. Rank hold BCRX as of Q3 2026.

  • Farther Finance Advisors held 6,138 shares of BioCryst Pharmaceuticals worth $51.1K as of Q3 2026.
  • Farther Finance Advisors sold 413 BioCryst Pharmaceuticals shares in Q3 2026, an estimated $3.89K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Farther Finance Advisors's portfolio in Q3 2026, its #3403 holding.
  • Farther Finance Advisors first reported a position in BioCryst Pharmaceuticals in Q1 2024 and has held it in 8 quarters since.
  • Farther Finance Advisors's BioCryst Pharmaceuticals position peaked at $89.6K in Q4 2025.
  • 11 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2026.

Based on Farther Finance Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.